Email this page Print this page

Mini-Review

Golimumab

Sohini Mazumdar and David Greenwald
Volume 1, Issue 5
September/October 2009
Pages 422 - 431

Purchase article for $19
Subscribe to this journal
» Log in

Golimumab, a human anti-TNFα IgG1κ monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications. The product was developed by Centocor and Janssen Pharmaceutical KK (Johnson & Johnson subsidiaries), in collaboration with Schering-Plough and Mitsubishi Tanabe Pharma. Golimumab faces numerous protein therapeutic competitors on the market, but, as the first patient-administered, once-monthly dosed anti-TNFα drug, it will likely be an attractive option for patients.


Authors

Sohini Mazumdar Corresponding author: sohini.mazumdar@tufts.edu
Tufts University School of Medicine
David Greenwald
Tufts University School of Medicine

Purchase article for $19
Subscribe to this journal
» Log in
Advertisements